BioSpace News Archive

IRADIMED CORPORATION (NASDAQ: IRMD) announced the retirement of Francis Casey, Vice President of Regulatory Affairs and Quality Assurance, effective June 30, 2020 after leading the Company’s regulatory efforts since 2004. IRADIMED appointed Steven Kachelmeyer as Vice President of Regulatory Affairs and Quality Assurance, succeeding Mr. Casey, effective March 10, 2020

NEW HAVEN, Conn., Feb. 26, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at two upcoming healthcare investor conferences. Conference Presentation Details: Event: Cowen and Co. 40th Annual Health Care Conferen

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800* (live modified horsepox virus vaccine for percutaneous administration) to protect against the new coronavirus disease, COVID-19, based on Tonix’s proprietary horsepox vaccine platform. Tonix is developing TNX-801 (live

-- Reported favorable interim data from Phase 1/2 study of M254 in ITP, supporting expansion of Part B; expect to report updated data in Q2 2020 and launch additional Phase 2 study in CIDP in Q4 2020 -- -- Target enrollment completed in nipocalimab Phase 2 Vivacity-MG study; top-line proof-of-concept results expected in Q3 2020 -- -- Expanded pipeline with nomination of M267, a new SIFbody development candidate targeting CD38; plan to initiate IND-enabling studies in 2020 -- -- Ended 2

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today that the American Journal of Transplantation (AJT) published data on AlloSure’s ability to differentiate ambiguous rejections, titled “High levels of dd-cfDNA identifies patients with TCMR 1A

Feb. 26, 2020 12:00 UTC CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD. Under the terms of the agreement, SERI and Gemini will explore the link between genetic and poten

Feb. 26, 2020 12:08 UTC Oisín Biotechnologies Included in MIT Technology Review’s “TR10” List of Top 10 Breakthrough Technologies of 2020 -- Oisín closes $3 million financing as it continues to move toward the clinic -- SEATTLE--( BUSINESS WIRE )-- Oisín Biotechnologies, a privately held, preclinical biotechnology company focused on mitigating the effects of age-related diseases, today announced that it has been included in MIT Technology Review ’s TR10 list of the Top

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that management will present at the Cowen 40 th Annual Health Care Conference on Monday, March 2, 2020 at 12:00 PM ET at the Boston Marriott Copley Place in Boston, MA. A live webcast of the presentation can be viewed on the company’s website at www.stemline.com .

HOLLISTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three and twelve months ended December 31, 2019. 4 th Quarter 2019 FY 2019 Revenue $31.0 million $116.2 million Operating Income (GAAP) $1.6 million $0.4 million Adjusted Operating Income / Margin $5.6 million, 18.1% $14.9 million, 12.8% Diluted EPS (GAAP) $0.01 $(0.12) Adjusted Diluted EPS $0.08 $0.18 Ji

CUPERTINO, Calif. , Feb. 26, 2020 /PRNewswire / -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and year ended December 31, 2019 financial results and host a conference call after the market close on Tuesday, March 3, 2020 . Tuesday March 3 rd @ 4:30pmET/1:30 p.m. Pacific Time Toll Free: 877-407-0